Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.88% | -31.23% | 123.69% | 278.09% | 647.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.88% | -31.23% | 123.69% | 278.09% | 647.88% |
| Cost of Revenue | 54.83% | 75.44% | 152.90% | 384.85% | 560.79% |
| Gross Profit | -35.92% | -35.46% | 121.85% | 272.40% | 652.50% |
| SG&A Expenses | -3.39% | 6.90% | 26.82% | 50.57% | 39.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.10% | 10.81% | 32.18% | 58.14% | 41.02% |
| Operating Income | -264.87% | -291.97% | 120.11% | 109.85% | 124.48% |
| Income Before Tax | -526.76% | -594.83% | 99.56% | 94.40% | 110.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -540.11% | -607.67% | 97.28% | 94.40% | 110.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -540.11% | -607.67% | 97.28% | 94.40% | 110.34% |
| EBIT | -264.87% | -291.97% | 120.11% | 109.85% | 124.48% |
| EBITDA | -201.29% | -182.13% | -- | -- | -- |
| EPS Basic | -533.14% | -634.35% | 98.26% | 94.97% | 110.12% |
| Normalized Basic EPS | -514.78% | -614.81% | 100.96% | 94.98% | 110.23% |
| EPS Diluted | -1,328.57% | -1,901.01% | 86.15% | 86.50% | 103.62% |
| Normalized Diluted EPS | -1,172.36% | -1,483.98% | 90.60% | 86.73% | 103.96% |
| Average Basic Shares Outstanding | 2.14% | 2.59% | 2.56% | 2.02% | 1.76% |
| Average Diluted Shares Outstanding | -1.60% | -1.19% | 6.41% | 5.86% | 5.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |